s.grahame

TL2 Member · Quebec City, CA

Practical questions, practical answers. Not interested in speculation without a source.

Joined 14 December 2024 · last posted 3d

83 posts, newest first. Showing up to 150.

Coming back to: A structured critique template this community uses Replied, post #68 · Evidence › Study critique · 25 Jul 2026 · 7 likes Where I part company with post #64, and it is a narrow parting. Practical experience of structured critique template, offered as one case with the conditions stated,…
What a reversed-phase purity number actually is Replied, post #81 · Analytics › HPLC & UHPLC · 22 Jul 2026 · 2 likes On reversed-phase purity number I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them…
Here for the analytics and not much else Replied, post #55 · Lounge › Introductions · 19 Jul 2026 · 6 likes Welcome aboard. If you post an introduction and then nothing for a month, nobody notices and nobody minds. Come back when there is something you want to know. I have…
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #88 · Access › International · 17 Jul 2026 · 7 likes Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is…
What a reversed-phase purity number actually is Replied, post #62 · Analytics › HPLC & UHPLC · 17 Jul 2026 · 0 likes A relative retention time against a known peak travels much better than an absolute one, and almost nobody reports it. Small point, but it is the one that usually…
Coming back to: Lateral-flow and colorimetric approaches: the specificity problem Replied, post #76 · Analytics › Home & field testing · 14 Jul 2026 · 5 likes Whatever the answer on Lateral-flow and colorimetric approaches turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in…
A supplier who responds to a discrepancy with silence — what changed since Replied, post #80 · Sourcing › Red flags · 13 Jul 2026 · 31 likes Supplier: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
Aggregate verification data across the directory, with caveats Replied, post #43 · Sourcing › Independent verification · 12 Jul 2026 · 23 likes Posting my aggregate verification data numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who wanted…
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #49 · Clinical › Bloodwork · 27 Jun 2026 · 0 likes Confirming post #46 from a second method, which matters more than confirming it from a second person. Liver enzymes drifting sits at the boundary between what this…
Revisiting: What pooling buys you and what it destroys Replied, post #69 · Evidence › Meta-analyses · 26 Jun 2026 · 26 likes When a meta-analysis is unhelpful: if the included studies are heterogeneous in population, intervention, or outcome, pooling them produces a number that represents…
[2026 update] Regional warehouse stock versus direct despatch Replied, post #101 · Sourcing › Logistics · 14 Jun 2026 · 1 like Tracking stops updating: tracking last updated days ago usually means the package is in transit and will not update until it reaches the next scanning point. No update…
Batch numbers that do not match the vial label Replied, post #21 · Sourcing › Red flags · 27 May 2026 · 19 likes Practical experience of batch numbers, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it…
About the COA interpretation category Replied, post #11 · Analytics › COA interpretation · 11 May 2026 · 28 likes I read post #7 twice before replying, because I had assumed the opposite. A chromatogram supplied as a small image is legible for peak shape and not for baseline…
A parcel stationary at a customs facility for nine days — does this still hold? Replied, post #17 · Sourcing › Logistics · 26 Apr 2026 · 0 likes The arithmetic in post #16 is right; the assumption feeding it is the part to check. Photographing the parcel on arrival before opening it takes ten seconds and is the…
Run-in periods and the population they select Replied, post #81 · Evidence › Trials · 13 Mar 2026 · 25 likes A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened…
Revisiting: The report format the maintainers ask for, and why each field is there Replied, post #32 · Sourcing › Vendor reports · 7 Mar 2026 · 0 likes A difference inside method repeatability is not a disagreement. Saying so in your own report prevents somebody else reading it as one.
Contributing data without breaching anyone's privacy Replied, post #69 · Data & Tools › Datasets · 6 Mar 2026 · 5 likes Date every record. A dataset assembled over two years without dates cannot distinguish a change over time from a change in who was contributing.
[2026 update] What a purity-only report leaves out Replied, post #41 · Sourcing › Independent verification · 2 Mar 2026 · 0 likes Everything in post #37 holds. The case it does not cover is the one I have. The record shows what was measured. Everything beyond that is inference and this site tries…
Why "dose equivalence" between different incretin analogues is a weak concept Replied, post #85 · Practice › Dosing & titration · 19 Feb 2026 · 9 likes The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The…
Where impurities in solid-phase peptide synthesis come from Replied, post #41 · Analytics › Impurities & related substances · 9 Feb 2026 · 0 likes Where an impurity is identified rather than merely counted, the certificate is telling you the manufacturer has characterised its own process. That is a meaningful…
PCOS and metabolic overlap: what is and is not studied Started this topic · Clinical › Comorbidities · 6 Feb 2026 · 0 likes On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. PCOS and metabolic overlap, from the point…
Endotoxin and why it is a separate question from purity Replied, post #2 · Analytics › Impurities & related substances · 5 Feb 2026 · 23 likes Thank you for the correction. I would rather find out here than later.
Muscle cramps: the ordinary causes before the exotic ones Replied, post #4 · Practice › Side effects · 12 Jan 2026 · 8 likes For anyone finding this later: the short answer on muscle cramps is that it depends on one thing, and the rest of the thread is people identifying which thing.
Coming back to: Private prescribing in the UK: what is actually involved Replied, post #43 · Regional › UK & Ireland · 6 Jan 2026 · 5 likes Cross-border movement between the two jurisdictions is not the same as domestic movement within either, and the rules are published rather than inferred.
A widely repeated interaction claim that turns out to be unsupported Replied, post #15 · Practice › Interactions · 29 Dec 2025 · 14 likes I had written a reply contradicting post #11 and deleted it. Here is what survived. Where a published interaction study exists it usually reports an area-under-curve…
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #25 · Practice › Interactions · 25 Dec 2025 · 3 likes Thank you for taking the time. That was more work than a reply usually is.
Interpreting a result that disagrees with the supplier's certificate Replied, post #44 · Sourcing › Independent verification · 15 Dec 2025 · 16 likes Where two services agree with each other and with the declared figure, that is a genuinely strong result and it applies to that lot. If it helps: the failure mode here…
Tirzepatide's shorter half-life and its one practical consequence Replied, post #30 · Compounds › Tirzepatide · 12 Dec 2025 · 21 likes Useful. I have added it to my own notes with the date on it.
Documentation that materially improves an appeal's chances Replied, post #91 · Access › Insurance & coverage · 5 Dec 2025 · 17 likes Narrowing post #88, because the general version has more than one answer. Reimbursement changes: a compound covered one year might not be the next. A formulary decision…
Follow-up: Constipation management, with a dietitian's contribution Replied, post #32 · Practice › Side effects · 22 Nov 2025 · 15 likes The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of…
Tirzepatide's shorter half-life and its one practical consequence Replied, post #9 · Compounds › Tirzepatide · 21 Nov 2025 · 0 likes Post #6 answers the question as asked. The question underneath it is different. The apnoea-hypopnoea index used in SURMOUNT-OSA is an objective measurement rather than…
Pen dose counters: what a click does and does not guarantee Replied, post #7 · Devices › Pens & autoinjectors · 12 Nov 2025 · 1 like A pen delivers a fixed or dialled dose from a cartridge and is a metering device rather than simply a covered syringe. That is why dose changes are constrained to…
Appeal templates and why they are deliberately unemotional Replied, post #22 · Access › Insurance & coverage · 11 Nov 2025 · 6 likes Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves…
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Replied, post #4 · Compounds › Tirzepatide · 3 Nov 2025 · 5 likes The published pharmacokinetics show dose proportionality across the studied range, which means dose arithmetic behaves the way you would naively expect. That is not…
Sleep tracking data and its considerable limitations Replied, post #66 · Wellbeing › Sleep · 23 Oct 2025 · 0 likes Narrowing post #63, because the general version has more than one answer. Appetite suppression and nighttime eating: if nighttime eating was a pattern, appetite…
Amylin receptor signalling and satiety Started this topic · Pharmacology › Receptor biology · 17 Oct 2025 · 3 likes Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. Asking about amylin receptor signalling and…
Follow-up: Why appetite effects are mostly central Replied, post #69 · Pharmacology › Receptor biology · 17 Oct 2025 · 14 likes Confirming post #68 from a second method, which matters more than confirming it from a second person. Appetite effects came up in a thread eighteen months ago and was…
Research-use-only labelling: what it means and what it does not Replied, post #43 · Sourcing › Regulatory · 8 Oct 2025 · 21 likes Post #40 answers the question as asked. The question underneath it is different. Nothing in this subcategory is legal advice, and the members who work in regulated…
Retatrutide's phase 2 heart-rate signal and how to think about it Replied, post #6 · Compounds › Retatrutide · 6 Oct 2025 · 12 likes Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The…
Second pass at: Coverage in the US: a map of the usual obstacles Replied, post #4 · Regional › North America · 6 Oct 2025 · 0 likes Canada: Health Canada licenses compounds. Prescribing is provincial. Compounds are prescription-only. Coverage varies between public and private insurance.
Column chemistry choices for a 40-residue peptide Replied, post #41 · Analytics › HPLC & UHPLC · 20 Sep 2025 · 0 likes Post #37 and I disagree about the size of the effect, not about the direction. On column chemistry choices I would separate what is worth knowing from what is worth…
Reverse causation in a cohort study of weight and outcome — a second dataset Replied, post #49 · Evidence › Study critique · 14 Sep 2025 · 12 likes Where I part company with post #47, and it is a narrow parting. Per-protocol and intention-to-treat analyses answer different questions and neither is the honest one by…
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #34 · Lounge › Off topic · 13 Sep 2025 · 0 likes Personal stories: if you want to talk about what led you to this compound, your journey, or how the change has affected your life, the Lounge is the place for that. I…
Hepatic impairment and the absence of data Replied, post #33 · Clinical › Special populations · 13 Sep 2025 · 24 likes Where a population is under-studied, registry data accumulates first and is confounded by indication in ways that are hard to correct. Flagging that the sources on this…
When a preprint is the best available evidence and we say so Replied, post #136 · Evidence › Preprints · 3 Sep 2025 · 0 likes Post #132 and I disagree about the size of the effect, not about the direction. Always label it as a preprint in any discussion. A preprint is not a published trial and…
Enforcement priorities versus written rules — does this still hold? Replied, post #40 · Sourcing › Regulatory · 1 Sep 2025 · 15 likes Careful with the language on Enforcement priorities. "Not detected" and "not present" are different findings and the first is a statement about the method.
Second pass at: Why this subcategory is stricter about sourcing than most Replied, post #110 · Compounds › Secretagogues & GH axis · 29 Aug 2025 · 5 likes Coming back to post #107, because the follow-up matters more than the original answer. Published human data on most of this family is thin, old, or from small studies…
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #88 · Access › Insurance & coverage · 21 Aug 2025 · 5 likes Marking my place. If it changes for me I will come back and say so.
How the vendor documentation pages are maintained, and by whom — what changed since Replied, post #36 · Sourcing › Vendor reports · 7 Aug 2025 · 0 likes Vendor documentation pages looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #2 · Evidence › Journal club · 5 Aug 2025 · 0 likes The opening post describes the usual case. This is about the unusual one. I keep a log for orforglipron phase 2 specifically because my memory of it turned out to be…
A ten-fold dose error caught before injection — one year on Replied, post #114 · Devices › Syringes & needles · 4 Aug 2025 · 0 likes Post #113 put the caveat in the right place and I want to underline it. The version of ten-fold dose error caught that I was taught turned out to be a teaching…
Thyroid function tests during substantial weight change Replied, post #18 · Clinical › Bloodwork · 31 Jul 2025 · 0 likes Rate of change is frequently more informative than absolute value, and it is only available if the earlier results were kept.
Subcutaneous absorption kinetics and site differences Replied, post #17 · Pharmacology › Pharmacokinetics · 22 Jul 2025 · 0 likes Worth separating two things that post #13 runs together. Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling…
Comparators chosen for regulatory reasons rather than clinical ones — one year on Replied, post #60 · Evidence › Trials · 23 Jun 2025 · 6 likes Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between…
What a documentation review can and cannot tell you Replied, post #6 · Sourcing › Independent verification · 15 Jun 2025 · 31 likes It does not extend to lots nobody has seen, it is not a recommendation, and it says nothing about anything other than what was measured. I have separated what I…
Journal club: STEP 4 and what a withdrawal design can prove Replied, post #45 · Evidence › Journal club · 25 May 2025 · 32 likes Post #42 answers the question as asked. The question underneath it is different. The baseline characteristics table is the single most useful page for the questions…
Splitting a vial for two laboratories: how to do it without ruining both Replied, post #44 · Sourcing › Independent verification · 21 May 2025 · 4 likes I think the splitting a vial question is answerable and has not been answered, which is a more optimistic position than most of this thread.
A ten-fold dose error caught before injection Replied, post #25 · Devices › Syringes & needles · 24 Apr 2025 · 22 likes Buying a box of the wrong barrel size is the most common regret described in this subcategory, and the reason is nearly always that the dose was decided after the…
Cost per milligram, computed honestly across formats — the long version Replied, post #60 · Access › Pricing · 9 Apr 2025 · 25 likes On post #56 — agreed on the reasoning, with one qualification. Nothing here is financial advice and none of it is a route to a transaction.
Carryover and the ghost peak from last week's standard Replied, post #37 · Analytics › HPLC & UHPLC · 5 Apr 2025 · 2 likes A relative retention time against a known peak travels much better than an absolute one, and almost nobody reports it. Worth saying I have only my own numbers here, and…
A report I filed that turned out to be wrong, and the correction Replied, post #4 · Sourcing › Vendor reports · 4 Apr 2025 · 1 like The maintainers will ask for missing fields rather than rejecting a report. Filling them in afterwards is normal and nobody minds.
Journal club: SURMOUNT-1, read without the press release Replied, post #89 · Evidence › Journal club · 2 Apr 2025 · 9 likes I read post #88 twice before replying, because I had assumed the opposite. Sessions on negative or null results are consistently the most instructive and the hardest to…
Comparators chosen for regulatory reasons rather than clinical ones — one year on Started this topic · Evidence › Trials · 22 Mar 2025 · 39 likes Comparators chosen for regulatory reasons rather than clinical ones — one year on — setting out what I have, and where I think it stops being reliable. Posting a small…
The C-cell question: rodent findings and their human context Started this topic · Compounds › Semaglutide · 13 Mar 2025 · 0 likes Posting this under the heading it deserves: The C-cell question: rodent findings and their human context Everything below is what sits behind that. The question about…
Biased agonism: a real phenomenon, an over-used explanation Replied, post #88 · Pharmacology › Receptor biology · 13 Mar 2025 · 17 likes On biased agonism, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the…
A 10 mg vial reconstituted three different ways, compared — the long version Replied, post #5 · Practice › Reconstitution · 27 Jan 2025 · 13 likes Two things can be true about 10 mg vial reconstituted three at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the…
Second pass at: Certificates issued by the seller versus by a laboratory Replied, post #57 · Analytics › COA interpretation · 25 Jan 2025 · 0 likes A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to sanity-check an integration and not enough to…
When "no data" is the complete and final answer Replied, post #72 · Compounds › Other compounds · 22 Jan 2025 · 7 likes Post #69 is the version of this I will quote in future. One addition. Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature,…
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #34 · Compounds › Semaglutide · 21 Jan 2025 · 8 likes Narrowing post #33, because the general version has more than one answer. Worth separating two things this subcategory keeps merging: what the molecule does, which is…
Swirling versus inverting versus leaving it alone Replied, post #3 · Practice › Reconstitution · 15 Jan 2025 · 5 likes Swirling until fully clear before drawing is worth the extra minute. A partially dissolved preparation is not uniform and the first dose out of it is not the same as…
Fixed versus detachable needles: the trade-offs Replied, post #61 · Devices › Syringes & needles · 20 Dec 2024 · 13 likes Coring the stopper is a real phenomenon with repeated entries at the same point and blunt needles. Varying the entry point slightly and using a fresh needle prevents…
People with a low starting BMI: where the evidence stops Replied, post #20 · Clinical › Special populations · 2 Dec 2024 · 0 likes Body weight at the extremes of the studied range affects exposure and the trials rarely reported enough to say by how much.
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #138 · Compounds › Repair & healing peptides · 24 Nov 2024 · 3 likes Anecdote is the whole of the human evidence base here, and this community's convention is to say so rather than to aggregate anecdotes into something that sounds like…
Meeting a protein target on a suppressed appetite — does this still hold? Replied, post #17 · Nutrition & Training › Protein & intake · 23 Nov 2024 · 2 likes I read post #15 twice before replying, because I had assumed the opposite. Adequate protein during a substantial deficit is the part of this conversation that gets…
Requesting a page: what makes a good request — what changed since Replied, post #42 · Documentation › Wiki requests · 10 Oct 2024 · 2 likes A request is more likely to succeed with a proposed outline attached. "Somebody should write about X" rarely moves; a structure and two sections does. That is where I…
The C-cell question: rodent findings and their human context — what changed since Replied, post #46 · Compounds › Semaglutide · 11 Sep 2024 · 18 likes Fair, and the limits you put on it are the part I will remember.
Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #10 · Compounds › Retatrutide · 30 Aug 2024 · 14 likes Worth separating two things that post #6 runs together. Marking my uncertainty on hepatic effects of glucagon receptor explicitly. I am confident about the direction,…
Follow-up: Dead volume across syringe and needle combinations Replied, post #23 · Devices › Syringes & needles · 19 Aug 2024 · 0 likes Since Dead volume across syringe keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more…
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset Replied, post #5 · Compounds › Secretagogues & GH axis · 14 Aug 2024 · 3 likes On post #3 — agreed on the reasoning, with one qualification. Worth stating the null on pulsatile secretion before we explain it: the observation may be nothing. That…
Coming back to: Preparing for an appointment: one page, three questions Replied, post #21 · Clinical › Prescriber conversations · 16 Jul 2024 · 4 likes Building on post #19 rather than restating it. Bringing a record of symptoms with dates and severities makes an assessment materially easier and is the single most…
The mass-error checker and its intended scope Replied, post #100 · Data & Tools › Calculators · 5 Jul 2024 · 10 likes Small correction to my own earlier position on mass-error checker. I had the units the wrong way round, which changes the conclusion by an order of magnitude and…
How this community labels and discusses unrefereed work Replied, post #33 · Evidence › Preprints · 22 Jun 2024 · 0 likes On community labels, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the…
Assessing a warm arrival: the decision process — one year on Replied, post #32 · Sourcing › Logistics · 29 May 2024 · 2 likes Split shipments reduce single-point risk and increase the number of transits. Which trade is right depends on what you are protecting against.